Visitors Now:
Total Visits:
Total Stories:
Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Sarepta licenses DMD treatment from Summit

Tuesday, October 4, 2016 6:57
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Sarepta Therapeutics Inc (NASDAQ:SRPT) has agreed a licensing deal worth up to US$522mln with the UK biotech Summit Therapeutics  PLC (LON:SUMM, NASDAQ:SMMT).

The pair will collaborate on Summit’s potentially breakthrough treatment for Duchenne muscular dystrophy (DMD), a muscle wasting disease that affects boys.

Sarepta is paying the UK drug developer an immediate US$40mln and US$22mln when the last patient in the company’s phase II trial is dosed.

DMD is caused by different mutations in the dystrophin gene that result in patients being unable to produce the protein that is essential for maintaining healthy muscle function.

Summit’s discovery is designed to increase the levels of another, similar, protein call utrophin.

This, it is hoped, will compensate for the lack dystrophin. The system is called utrophin modulation.

Sarepta’s chief executive, Edward Kaye, said: “Summit’s utrophin modulation technology represents a potentially promising approach to treat DMD, which may complement our current approach of exon skipping therapy.”

Duchenne muscular dystrophy, or DMD, is one of the most common, fatal genetic disorders diagnosed in children around the world.

It predominantly affects boys and it results in the progressive wasting of muscles throughout the body.

The disease has an estimated incidence of 1 in 5,000 and a patient population in the developed world of around 50,000. Patients typically don’t live beyond their late twenties.

Story by ProactiveInvestors

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.